[Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper]

Wien Med Wochenschr. 2018 Apr;168(5-6):133-143. doi: 10.1007/s10354-017-0548-4. Epub 2017 Feb 24.
[Article in German]


Edoxaban is the most recent available representative of the Non-Vitamin K antagonist oral anticoagulants (NOAC). The approval was based on the largest phase III trials of NOACs for stroke prevention in patients with non-valvular atrial fibrillation (AF, ENGAGE-AF), and for the treatment of venous thromboembolism (VTE, HOKUSAI-VTE). In both trials, edoxaban was associated with similar efficacy and a significant reduction in bleeding events with respect to the pre-defined primary safety endpoints, as compared to warfarin.Additionally, the once daily dosing of edoxaban, the clinically investigated strategy for dose-reduction based on clearly defined criteria and the favorable pharmacokinetic profile might further support the clinical applicability of the substance.In the light of recent data, this expert consensus document aims to summarize the latest clinical trial results while providing a concise overview of current guideline recommendations on the management of patients with non-valvular AF and VTE.

Keywords: Atrial fibrillation; Edoxaban; Non-Vitamin K antagonist oral anticoagulants; Venous thromboembolism.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Anticoagulants
  • Atrial Fibrillation* / prevention & control
  • Factor Xa Inhibitors / therapeutic use*
  • Humans
  • Pyridines / therapeutic use*
  • Stroke*
  • Thiazoles / therapeutic use*
  • Venous Thromboembolism* / prevention & control


  • Anticoagulants
  • Factor Xa Inhibitors
  • Pyridines
  • Thiazoles
  • edoxaban